I am a board certified nuclear radiologist by the American Board of Nuclear Medicine, American Board of Radiology and American Board of Nuclear Cardiology. I am a reviewer of 16 international journals including Journal of Nuclear Medicine; European Journal of Nuclear Medicine and Molecular Imaging; Proceedings of the National Academy of Sciences (PNAS); International Journal of Computer Assisted Radiology and Surgery; PLOS ONE; Academic Radiology; Cancer Control Journal: Journal of the Moffitt Cancer Center; Medical Physics; International Journal of Radiation Oncology, Biology, Physics; Theranostics and Lung Cancer Management published by Future Medicine. I am an editorial board member of Chinese Journal of Cancer Research. I am also a reviewer of the Self-Assessment Module (SAM) for the American Board of Radiology.
My research experience includes metabolic tumor imaging and quantification from FDG PET/CT imaging, and the impact of metabolic tumor burden on the long-term outcomes of patients with non-small cell lung cancer (NSCLC). I was the contact co-PI of an NIH (NCI) funded R21 project for developing the new PET volumetric prognostic (PVP) staging for NSCLC. My research experience also includes brain functional imaging and brain MRS as well as computer-aided diagnosis in PET/CT and bone scintigraphy.
I have authored and co-authored more than 60 original peer-reviewed scientific research papers, six peer-reviewed proceeding papers, two non-peer-reviewed letters to editors and five non-peer-reviewed review papers in the field of medicine. I am the senior corresponding author of the article [Eur J Nucl Med Mol Imaging, 2012; 39(1): 27-38. https://www.ncbi.nlm.nih.gov/pubmed/21946983] that won the Springer Award in 2016 for the Most Cited Paper of the Eur J Nucl Med Mol Imaging (https://link.springer.com/article/10.1007/s00259-016-3538-7).
Weil Medical College of Cornell University
New York
Residency - Radiology
2004
Mallinckrodt Institute of Radiology at Washington University
St. Louis, MO
Residency - Nuclear Medicine
2003
Beijing Medical University
Beijing
PHD - Radiology
1989
Beijing Medical University
Beijing
MD Equivalent - Medicine
1984
Comparison of Measurement and Prognostic Power of SUV Between High-Definition and Standard PET Imaging in Non-Small Cell Lung Cancer Patients.
Comparison of Measurement and Prognostic Power of SUV Between High-Definition and Standard PET Imaging in Non-Small Cell Lung Cancer Patients. J Nucl Med Technol. 2024 Sep 05; 52(3):229-233.
PMID: 39019575
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2023 Sep 16.
PMID: 37827881
Whole-body tumor segmentation from PET/CT images using a two-stage cascaded neural network with camouflaged object detection mechanisms.
Whole-body tumor segmentation from PET/CT images using a two-stage cascaded neural network with camouflaged object detection mechanisms. Med Phys. 2023 Oct; 50(10):6151-6162.
PMID: 37134002
Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy.
Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy. Front Biosci (Landmark Ed). 2022 01 12; 27(1):16.
PMID: 35090321
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
PMID: 33881502
The Relative Importance of Clinical and Socio-demographic Variables in Prognostic Prediction in Non-Small Cell Lung Cancer: A Variable Importance Approach.
The Relative Importance of Clinical and Socio-demographic Variables in Prognostic Prediction in Non-Small Cell Lung Cancer: A Variable Importance Approach. Med Care. 2020 05; 58(5):461-467.
PMID: 31985586
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma.
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417.
PMID: 30198643
An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2018 09; 123:136-141.
PMID: 30089584
Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.
Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2079-2092.
PMID: 29882161
Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation.
Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation. Eur J Hybrid Imaging. 2017; 1(1):8.
PMID: 29782599
Most cited paper in European Journal of Nuclear Medicine and Molecular Imaging
European Association of Nuclear Medicine and Springer
2016
Certifier for Highly Cited Research
Academic Radiology
2016
Grant reward (R21): Developing a PET Volumetric Staging System for NSCLC
The National Cancer Institute of the National Institutes of Health
2014 - 2018
Marc Tetalman Award for Outstanding Teaching
Department of Radiology of the university of Chicago
2006
Roentgen Resident/Fellow Research Award
Radiological Society of North America Research & Education Foundation
2003